Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

October 4, 2022

Study Completion Date

October 4, 2022

Conditions
Neoplasms
Interventions
OTHER

Screening Platform

Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.

Trial Locations (3)

32608

GSK Investigational Site, Gainesville

50701

GSK Investigational Site, Waterloo

65807

GSK Investigational Site, Springfield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05100316 - Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials | Biotech Hunter | Biotech Hunter